Posts tagged medical device
PureTech targeting dysfunctions in brain, gut, immune system

With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious diseases caused by dysfunctions in the brain, gut and immune system.

Read More
FeatureLeonard Zehrclinical study, clinical-stage, pivotal trial, PureTech, PureTech Health, LSE:PRTC, drug, drug development, diseases, chronic diseases, Bharatt Chowrira, Drs Chowrira, disease progression, slowing disease, halting disease, reversing disease, chronic, chronic disease, slow disease progression, detection, chronic disease treatment, biopharma, biopharmaceutical company, innovative approach, GI, gastrointestinal, obesity, bariatric surgery, Pharmaceuticals, obese, oral, oral therapy, oral therapies, GI tract, gastrointestinal tract, Gelesis100, Gelesis, transformative, transformative treatment, medical device, drug absorption, nutrient absorption, body weight loss, overweight, prediabetes, type 2 diabetes, obesity related diseases, fatty liver disease, osteoarthritis, cardiovascular, cardiovascular disease, non-alcoholic fatty liver disease, diabetes, diabetes therapy, Gelesis200, Gelesis 200, Gelesis 100, glycemic, glycemic control, liver disease, liver, proof-of-concept, preclinical, immune, aging population, innovation investment, immunosenescence, aging immune system, respiratory tract infections, pneumonia, influenza, mTOR, mTORC1, immune-enhance, Phase 2, peer-reviewed studies, RTB 101, cold, flu, Akili, ADHD, Attention Deficit Hyperactivity Disorder, Project:EVO, Alzheimer’s, Alzheimer's disease, Pfizer, digital medicine platform, cognitive science, Adam Gazzaley, Dr. Adam Gazzaley, UCSF, Dr. Gazzaley, elderly, elder patients, ADHD treatment, Internation Conference on Clinical Trails for Alzheimer's disease, pipeline, LSE, PRTC
In conversation with John Gannon of TempTraq

As president and CEO of closely-held Blue Spark Technologies and co-inventor of its newest product, TempTraq, John Gannon’s career has stretched from the aerospace industry to Wall Street, culminating in 2011 with this developer of thin, flexible printed batteries built on IP from Eveready Battery, now Energizer. He has worked as an engineer in GE’s Astro-Space division and in currency derivatives with Merrill Lynch in New York and Barclays Capital in London...

Read More
Histogenics to complete Phase 3 enrollment in Q2

Histogenics (NASDAQ:HSGX) expects to complete enrollment by the end of the second quarter this year in a Phase 3 clinical trial of its NeoCart biologic cell therapy and tissue engineering solution for knee cartilage regeneration.

Read More
In conversation with Amir Ronen

As a founding member of closely-held Sensible Medical Innovations, Amir Ronen also has held the title of CEO since the company’s inception in late 2007. Mr. Ronen has over 15 years of experience in senior management roles at leading global companies, including VP of marketing and business development at M-Systems, which was acquired by Sandisk; as a senior strategic planning manager at Intel; and as VP of strategic alliances at Saifun, which was acquired by Spansion. In this interview with BioTuesdays.com, Mr. Ronen discusses the company’s solution for managing and reducing readmissions of patients with heart failure – a novel sensor, used once a day for 90 seconds, to provide an accurate measurement of lung fluid content.

Read More
In conversation with Dr. Alan Schwebel

As president and CEO of BioView (TASE:BIOV), Dr. Alan Schwebel has led the company, a world leader in automated fluorescence in situ hybridization (FISH) cell imaging and analysis, since 2009. Dr. Schwebel, who has more than 30 years of experience in senior management positions in leading medical device and medical diagnostic companies, joined BioView in 2002 as VP of sales and marketing. In this interview with BioTuesdays.com, he discusses the company’s cutting-edge technology, exclusive worldwide distribution and development agreements with Abbott Molecular and a new lung cancer diagnostic test.

Read More